Back to search

National and Kapodistrian University of Athens

Cancer biomarkers for immune and targeted therapy

Abstract

dc:description

PURPOSE Analyzing biomarkers in cancer offers insights that go beyond traditional clinical factors, helping to identify patients who are likely to have a more favorable balance of benefits and risks with specific treatments. This biomarker study centers on two types of epithelial cancers: Head and Neck Squamous Cell Carcinoma (HNSCC) and Breast Cancer (BC). PATIENTS AND METHODS Samples from forty-one HNSCC patients that were randomized to Cisplatin plus Olaparib (Arm A), Olaparib alone (Arm B), no treatment (Arm C) or Durvalumab plus Olaparib (Arm D) were used to evaluate for pre-specified biomarkers. Cell lines and tissue microarrays (TMAs) were used to examine the dynamic range of HER2 biomarker and develop an assay specific to low HER2 expression and then to determine the prevalence of low-level expression in each specimen from a serial, retrospective collection of breast cancer cases. RESULTSA reduction in Ki67 by at least 25% was detected in 44.8% of patients receiving treatment, as determined through quantitative immunofluorescence (QIF). Post-treatment, PD-L1 levels (measured by Combined Positive Score) were notably elevated in groups (A) and (D). There was a significant increase in the expression of CD163 and Colony Stimulating Factor 1 Receptor (CSF1R) genes—markers associated with M2 macrophages—while the expression of CD80, an M1 macrophage marker, decreased. Through calculations of detection limits, quantification, and assay linearity, we established that the expression range of HER2 in non-amplified cell lines lies between 2 and 20 attomol/mm². CONCLUSION Treatment with olaparib influences the tumor microenvironment by increasing PD-L1 levels and promoting pro-tumor characteristics in macrophages. When this assay was applied to a sequential cohort of 364 breast cancer cases from Yale, results showed that 67% of the cases had HER2 expression above the quantification limit but below the levels typical of HER2-amplified breast cancer.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2024

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Moutafi, Myrto
  • Μουτάφη, Μυρτώ

Subjects

dc:subject × 16

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/58406

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Moutafi, Myrto; Μουτάφη, Μυρτώ. Cancer biomarkers for immune and targeted therapy. National and Kapodistrian University of Athens, 2024. http://hdl.handle.net/10442/hedi/58406